Abstract:
:Immunomodulatory cell therapy as a complement to standard pharmacotherapy represents a novel approach to solid organ allograft acceptance. This methodology may allow for a reduced dose of immunosuppressive drug to be administered and thus attenuate the severe side effects associated with long-term immunosuppression such as drug-related impairment of renal function, increased risk from opportunistic infections and malignancies. Mesenchymal stem cells (MSCs) have been shown to possess both immune modulatory and regenerative properties in vitro and in preclinical models. Encouraging results have been reported from studies examining the safety and efficacy of MSCs as a treatment for acute graft-versus-host disease. MSCs represent a promising candidate cell therapy to supplement immunosuppression in recipients of solid organs, and initial reports on the clinical use of MSCs in kidney transplantation have been recently published (Tan et al. in J Am Med Assoc 307:1169-1177, 2012; Reinders et al. in Stem Cells Transl Med 2:107-111, 2013; Perico et al. in Transpl Int 26:867-878, 2013; Perico et al. in Clin J Am Soc Nephrol 6:412-422, 2011). An area of even greater interest might be the application of MSCs in clinical liver transplantation as graft survival is closely associated with overall patient survival. Here, we present preclinical findings and discuss their possible impact on clinical liver transplantation. Then we discuss clinical studies designed to investigate how MSCs may be distributed and act in solid organ transplantation.
journal_name
Hepatol Intjournal_title
Hepatology internationalauthors
Benseler V,Obermajer N,Johnson CL,Soeder Y,Dahlke MD,Popp FCdoi
10.1007/s12072-013-9509-1subject
Has Abstractpub_date
2014-04-01 00:00:00pages
179-84issue
2eissn
1936-0533issn
1936-0541pii
10.1007/s12072-013-9509-1journal_volume
8pub_type
杂志文章abstract:BACKGROUND:Although clinical and experimental studies have demonstrated a correlation between obstructive jaundice and the development of sepsis, the mechanism has not been fully elucidated. PURPOSE:The aim of this study was to investigate the influence of biliary obstruction on bacterial translocation as a possible s...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-007-9018-1
更新日期:2007-12-01 00:00:00
abstract:BACKGROUND:L-Asparaginase is a bacterial enzyme used in the treatment of acute lymphoblastic leukemia. In the ongoing U.S. Drug-Induced Liver Injury Network (DILIN) prospective study, standard and pegylated asparaginase were the most frequent cause of liver injury with jaundice among anti-cancer agents (8 of 40: 20%). ...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-019-09971-2
更新日期:2019-09-01 00:00:00
abstract:BACKGROUND/PURPOSE:In Japan, there is a growing population of patients with chronic hepatitis C virus (HCV) infection who failed a direct-acting antiviral (DAA)-based regimen. In this Phase 3 study, we evaluated sofosbuvir-velpatasvir plus ribavirin in Japanese patients with genotype 1 or 2 HCV infection who previously...
journal_title:Hepatology international
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s12072-018-9878-6
更新日期:2018-07-01 00:00:00
abstract::Actinomycotic hepatic abscess was diagnosed in a 46-year-old male driver from Ukraine presenting with the symptoms of malaise, loss of appetite, upper right quadrant pain, weight loss, and night sweats which had been present for last 2 months. Computed tomography (CT) of the abdomen revealed a hypodense mass in the le...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-007-9032-3
更新日期:2008-03-01 00:00:00
abstract:BACKGROUND AND AIMS:Recently, Sofosbuvir was launched in India at affordable cost. We conducted a real-life study to determine the efficacy and safety of Sofosbuvir plus Ribavirin, with and without peginterferon-alfa 2a, in patients with chronic hepatitis C (CHC) genotype 3, the commonest genotype in South Asia. METHO...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-017-9794-1
更新日期:2017-05-01 00:00:00
abstract::To address the relationship between hepatitis B virus (HBV) endemicity and HBV-related liver diseases in Mexico. Research literature reporting on HBsAg and antibody to hepatitis B core antigen (anti-HBc) prevalence in Mexican study groups were searched in NLM Gateway, PubMed, IMBIOMED, and others. Weighted mean preval...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-008-9115-9
更新日期:2009-06-01 00:00:00
abstract:BACKGROUND:Initial presentation of hepatocellular carcinoma (HCC) at an advanced stage in patients under a regular surveillance program is a devastating problem. AIMS:We assessed the prevalence and factors associated with this surveillance failure. METHODS:A total of 304 HCC patients who received regular surveillance...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-013-9462-z
更新日期:2013-10-01 00:00:00
abstract:BACKGROUND AND AIMS:To estimate the impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma. METHODS:We searched Pubmed and Embase for original articles that evaluated the impact of hepatitis B virus infection on outcomes of intrahepatic cholangiocarcinoma. The present study was conducted to ...
journal_title:Hepatology international
pub_type: 杂志文章,meta分析,评审
doi:10.1007/s12072-018-9881-y
更新日期:2018-07-01 00:00:00
abstract:BACKGROUND:There is much controversy surrounding the natural history of hepatitis C virus (HCV) infection. AIMS:The aim of this review was to review the natural history of HCV infection. METHODS:Published English literature was searched via pubmed and then reviewed. RESULTS:Approximately, 75-85% of HCV-infected pers...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-012-9355-6
更新日期:2012-10-01 00:00:00
abstract:PURPOSE:Either combination treatment or monotherapy using agents with a high genetic barrier are recommended for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). The aim of this study was to compare effect of naïve HBeAg-negative CHB patients with either de novo combination of lamivudine (LAM) and adef...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-010-9243-x
更新日期:2011-06-01 00:00:00
abstract:BACKGROUND AND AIM:Relationships between circulating microRNA-122 (miR-122) and histological features of nonalcoholic fatty liver disease (NAFLD) are unclear. METHODS:The impact of serum miR-122 levels for histological features and hepatocellular carcinoma (HCC) was investigated in 305 Japanese patients with histologi...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-016-9729-2
更新日期:2016-07-01 00:00:00
abstract:PURPOSE:There have been reports that radiofrequency ablation (RFA) combined with transarterial chemoembolization (TACE) is as equally effective as surgical resection for the treatment of hepatocellular carcinoma (HCC). This study aimed to evaluate recurrence rate and risk factor of recurrence after RFA combined with TA...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-011-9290-y
更新日期:2012-04-01 00:00:00
abstract::Along with the obesity epidemic, the prevalence of nonalcoholic fatty liver disease (NAFLD) has increased exponentially. The histological disease spectrum of NAFLD ranges from bland fatty liver (hepatic steatosis), to the concomitant presence of inflammation and ballooning which defines nonalcoholic steatohepatitis (N...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-015-9689-y
更新日期:2016-05-01 00:00:00
abstract:PURPOSE:Despite improvements in immunosuppressive therapy, acute cellular rejection (ACR) remains an important cause of graft loss in patients undergoing liver transplantation. Recently, associations between cytokine gene polymorphisms in recipients and the occurrence of ACR have been reported. However, most studies di...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-013-9443-2
更新日期:2013-07-01 00:00:00
abstract::The presence of hepatic encephalopathy (HE) within 4 weeks is part of the criteria for defining acute-on-chronic liver failure (ACLF). The pathophysiology of HE is complex, and hyperammonemia and cerebral hemodynamic dysfunction appear to be central in the pathogenesis of encephalopathy. Recent data also suggest that ...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-015-9626-0
更新日期:2015-10-01 00:00:00
abstract:BACKGROUND AND AIMS:Acute-on-chronic liver failure (ACLF) is associated with a high mortality rate in the absence of liver transplantation. There is limited data on predictors of survival in ACLF in children. Therefore, we prospectively studied the predictors of outcome of ACLF in children. METHODS:A prospective evalu...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-010-9217-z
更新日期:2011-06-01 00:00:00
abstract::Patients (85%) with hepatocellular adenoma (HCA) are women taking oral contraceptives. They can be divided into four subgroups according to their genotype/phenotype features. (1) Hepatocyte nuclear factor 1alpha (HNF1alpha) biallelic somatic mutations are observed in 35% of the HCA cases. It occurs in almost all cases...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-008-9075-0
更新日期:2008-09-01 00:00:00
abstract:BACKGROUND AND AIMS:Coagulopathic bleeding risk prediction is challenging in decompensated cirrhosis (DC) by conventional assays. Viscoelastic tests (VETs) are likely to be more useful for assessing coagulation status in these patients. We investigated whether the VET (Sonoclot) parameters with fibrinogen could predict...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-020-10036-y
更新日期:2020-07-01 00:00:00
abstract::Hepatitis B virus (HBV) reactivation with hepatic decompensation leading to acute on chronic liver failure is not uncommon. It is associated with high mortality of up to 30-70%. Prognostic factors for mortality include high bilirubin level, more prolonged prothrombin time, low platelet count and presence of pre-existi...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-014-9569-x
更新日期:2015-07-01 00:00:00
abstract::Hepatitis C virus (HCV) treatment in HIV/HCV co-infected individuals has renewed relevance given the ongoing opioid crisis and rise of new HIV and HCV infections associated with injection drug use. Patients co-infected with HIV and HCV demonstrate increased rates of hepatic fibrosis, progression to liver failure, and ...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-018-9896-4
更新日期:2018-11-01 00:00:00
abstract:BACKGROUND:Early prediction of lamivudine (LAM) response by individualized monitoring of serum HBV DNA like roadmap concept, and investigation of the outcome after LAM discontinuation in renal transplant recipients (RTRs) with chronic hepatitis B (CHB). METHODS:We conducted a study on 19 RTRs with HBV infection receiv...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-011-9295-6
更新日期:2012-04-01 00:00:00
abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is one of the most common malignant neoplasms worldwide. The p53 gene is frequently mutated in some histological subtypes of HCC. The role of p53 mutations and polymorphic variant of codon 72 in the prognosis of disease is still unclear. The p53 tumor suppressor gene Arg72Pro p...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-012-9389-9
更新日期:2013-06-01 00:00:00
abstract::The cancer stem cell (CSC) hypothesis has been disproved in many cancers. CSCs may exist in blood cancer, while many epithelial cancers may not have CSCs but tumor-initiating cells (TICs). Several independent studies have provided strong evidence for existence of CSCs in brain, skin, and colon cancers (Mani et al. in ...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-016-9777-7
更新日期:2017-03-01 00:00:00
abstract:BACKGROUND:Sorafenib significantly improves survival in patients with advanced hepatocellular carcinoma (HCC). This phase IV study assessed sorafenib efficacy/safety in Taiwanese patients with advanced HCC and Child-Pugh A status. METHODS:All patients received 400 mg sorafenib BID. Safety, efficacy, sorafenib pharmaco...
journal_title:Hepatology international
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s12072-016-9774-x
更新日期:2017-03-01 00:00:00
abstract::Hepatocellular carcinoma (HCC) is a common malignant tumor with high lethality, and the hepatitis B virus (HBV) is a chief cause. HBV can accelerate HCC via multiple mechanisms. First, HBV induces immune reactions that lead to repeated hepatic inflammation, fibrosis and a deficient immune microenvironment. Subsequentl...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-016-9779-5
更新日期:2017-03-01 00:00:00
abstract:PURPOSE:To analyze the prognostic factors for the patients with lung metastases from hepatocellular carcinoma (HCC). METHODS AND MATERIALS:One hundred and five patients with lung metastases from HCC were analyzed retrospectively. We analyzed the impact factors, including the gender, age, liver function, serum AFP and ...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-008-9052-7
更新日期:2008-06-01 00:00:00
abstract:BACKGROUND AND AIM:There is an increased awareness of de novo hepatitis B virus (HBV) infection (DNH) in hepatitis B surface antigen (HBsAg)-negative recipients receiving hepatitis B core antibody (HBcAb)-positive liver organ. Whether hepatitis B surface antibody (HBsAb) has positive result on preventing the occurrence...
journal_title:Hepatology international
pub_type: 杂志文章,meta分析
doi:10.1007/s12072-020-10021-5
更新日期:2020-03-01 00:00:00
abstract:BACKGROUND AND AIMS:The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatit...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-012-9395-y
更新日期:2013-06-01 00:00:00
abstract::Chronic hepatitis B virus (HBV) infection is a major global health burden and cure is rarely achieved by current antiviral therapies. Therefore, there is an urgent need for new therapeutic options. Immune modulation with the goal to restore dysfunctional HBV-specific immunity is an interesting target for new therapeut...
journal_title:Hepatology international
pub_type: 杂志文章,评审
doi:10.1007/s12072-018-9912-8
更新日期:2019-03-01 00:00:00
abstract:PURPOSE:Hepatitis B viral markers may be useful for predicting outcomes such as liver-related deaths or development of hepatocellular carcinoma. We determined the frequency of these markers in different clinical stages of chronic hepatitis B infection. METHODS:We compared baseline hepatitis B viral markers in 317 pati...
journal_title:Hepatology international
pub_type: 杂志文章
doi:10.1007/s12072-010-9179-1
更新日期:2010-04-07 00:00:00